VivoSeq
Other

Aggressive Behavior

11

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Aggressive Behavior is an emerging landscape with 11 programs across 6 companies. The most active players are Azevan Pharmaceuticals, Boehringer Ingelheim, Johnson & Johnson Taiwan Ltd. 6 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

6/100

Mech. Concentration

11/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Azevan Pharmaceuticals

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2J

Johnson & Johnson Taiwan Ltd

1 program

Phase 2Novartis logo

Novartis

1 program

ApprovedS

Solvay Pharmaceuticals

1 program

ApprovedOtsuka logo

Otsuka

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Not yet recruiting1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
Not yet recruiting·AAzevan Pharmaceuticals·Phase 2·NCT07328529·80 enrolled
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Completed·Novartis logoNovartis·Phase 4·NCT00154362·50 enrolled
Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.
Completed·IIndiana University School of Medicine·Phase 2·NCT00550147·30 enrolled
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
Recruiting·Otsuka logoOtsuka·N/A·NCT06875986·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)